Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antifungal agents.

Aditya K Gupta1, Elizabeth Tomas

  • 1Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook Site), University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. agupta@execulink.com

Dermatologic Clinics
|September 6, 2003
PubMed
Summary

New antifungal drugs and formulations offer improved efficacy and reduced toxicity compared to standard treatments. Research highlights novel azoles, liposomal amphotericin B, and echinocandins for various fungal infections, addressing drug resistance challenges.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onychomycosis in Diabetics: A Common Infection with Potentially Serious Complications.

Life (Basel, Switzerland)·2025
Same author

Artificial Intelligence and Large Language Models in the Fight Against Superficial Fungal Infections: Friend or Foe?

Clinical, cosmetic and investigational dermatology·2025
Same author

Understanding the evolving treatment landscape of hidradenitis suppurativa: An analysis of All of Us.

PloS one·2025
Same author

Onychomycosis in special populations.

Future microbiology·2025
Same author

Management and Genetics of Alopecia Areata within the USA: A Cross-Sectional Study of All of Us.

Skin appendage disorders·2025
Same author

A Canadian Algorithm on the Management of Telogen Effluvium.

Journal of cutaneous medicine and surgery·2025

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Standard antifungal therapies face limitations due to toxicity, low efficacy, and emerging drug resistance.
  • New antifungal formulations and agents are being developed to enhance treatment outcomes for superficial and systemic fungal infections.

Purpose of the Study:

  • To review the therapeutic potential of novel antifungal agents and formulations.
  • To discuss their efficacy, toxicity profiles, and mechanisms of action in combating fungal infections.
  • To address the challenge of antifungal drug resistance.

Main Methods:

  • Review of current literature on new antifungal drugs and formulations.
  • Analysis of efficacy and toxicity data for liposomal amphotericin B, new azoles (voriconazole, ravuconazole, posaconazole), and echinocandins (caspofungin).

Related Experiment Videos

  • Discussion of antifungal resistance mechanisms and susceptibility testing.

    • Main Results:

    • Liposomal amphotericin B shows broad-spectrum activity against invasive fungi with reduced toxicity and comparable or superior efficacy to standard formulations.
    • New triazole antifungals (voriconazole, ravuconazole, posaconazole) demonstrate broad-spectrum activity for systemic and superficial infections.
    • Echinocandins, like caspofungin, target fungal cell wall synthesis and are approved for invasive aspergillosis and candidiasis.

    Conclusions:

    • Novel antifungal agents and formulations offer promising alternatives to overcome limitations of current therapies.
    • Antifungal drug resistance, including cross-resistance and heterogeneity in susceptibility, requires ongoing monitoring and further research.
    • Standardized susceptibility testing is crucial for effective antifungal treatment strategies.